Goldman Sachs
PRVL

Goldman Sachs’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Goldman Sachs’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-293,489
Closed -$6.77M – 6578
2020
Q4 		$6.77M Buy
293,489
+237,045
+420% +$3M ﹤0.01% 2773
2020
Q3 		$575K Buy
56,444
+24,067
+74% +$323K ﹤0.01% 4410
2020
Q2 		$482K Buy
32,377
+11,712
+57% +$180K ﹤0.01% 4398
2020
Q1 		$252K Buy
20,665
+5,086
+33% +$80.9K ﹤0.01% 4604
2019
Q4 		$247K Buy
+15,579
New +$199K ﹤0.01% 4825
2019
Q3 		– Sell
-37,642
Closed -$497K – 5483
2019
Q2 		$497K Buy
+37,642
New +$549K ﹤0.01% 4404

Goldman Sachs's PRVL Position: Q1 2021 in Review

Goldman Sachs sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 293,489 shares — an estimated $6.77M sold.

Goldman Sachs first reported a position in PRVL in Q2 2019 and held it in 6 quarters. The position peaked at $6.77M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Goldman Sachs reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Goldman Sachs sold 293,489 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $6.77M.
  • Goldman Sachs first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 6 quarters.
  • Goldman Sachs's Prevail Therapeutics Inc. Common Stock position peaked at $6.77M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Goldman Sachs's 13F filing for Q1 2021, filed 17 May 2021.